The Complexity of Treating Pediatric Migraine

Source: Gargari OK, Aghajanian S, Togha M, et al. Preventive medications in pediatric migraine: a network meta-analysis. JAMA Netw Open. 2024;7(10):e2438666; doi: 10.1001/jamanetworkopen.2024.38666.Investigators from multiple institutions, primarily in Iran, conducted a systematic review and meta-analysis to assess the effectiveness of pharmacologic agents as prophylaxis against migraine headaches in children and adolescents. A standardized process was used to identify randomized trials of drugs compared against each other, or against placebo, for migraine prophylaxis among patients <18 years old. All assessed medications were administered orally. Outcomes included headache frequency (number of migraine attacks per month), reduction in frequency of 50% or more, headache duration, headache intensity, and disability from migraine headaches, as assessed using the pediatrics migraine-specific disability tool (PedMIDAS). Data from studies that included 1 or more of these outcomes were pooled for the meta-analyses and ratio of means (RoM) or risk ratio (RR) calculated. The effectiveness of different drugs for various outcomes were ranked using P scores.Overall, 45 trials with 3,771 participants were included in the analysis. Reduction in headache frequency was assessed in 37 trials with 2,617 patients. Compared with placebo, there was a statistically significant reduction in headache frequency associated with use of pregabalin, topiramate with vitamin D3, flunarizine, levetiracetam, riboflavin, cinnarizine, topiramate, and amitriptyline. Using P scores, the top 3 rated treatments were pregabalin, topiramate with vitamin D3, and levetiracetam; use of pregabalin was associated with a 62% reduction in headache frequency. A ≥50% reduction in headache frequency was assessed in 29 studies that included 2,801 participants. Flunarizine and alpha-lipoic acid (RR, 8.73; 95% confidence interval [CI], 2.44, 31.20), flunarizine alone (RR, 4.00; 95% CI, 1.38, 11.55), pregabalin (RR, 1.88; 95% CI, 1.13, 3.14), and cinnarizine (RR, 1.46; 95% CI, 1.04, 2.05) each significantly outperformed placebo in achieving this outcome. Headache intensity was evaluated in 19 studies. Compared to placebo, propranolol and cinnarizine, pregabalin, valproate, levetiracetam, and cinnarizine each were associated with significantly lower headache intensity. None of the medications tested in the meta-analysis were associated with significant reduction in disability from migraines, and none were associated with significantly reduced headache duration.The authors conclude that topiramate and pregabalin treatments were associated with a reduction in migraine headache frequency and intensity in children and adolescents.Dr Badawi has disclosed no financial relationship relevant to this commentary. This commentary does not contain a discussion of an unapproved/investigative use of a commercial product/device.The current investigators address a critical gap in pediatric neurology: identifying effective preventive treatments for migraines in children and adolescents. As the authors note, pediatric migraines are a significant public health concern, with an estimated prevalence of 11% globally, impacting quality of life and academic performance. The American Academy of Neurology published guidelines for pharmacologic pediatric migraine prophylaxis,1 noting that in most studies there was not a significant difference noted between placebo and medication. The current study provides evidence for improvement in specific outcomes.None of the treatments improved quality of life as measured by the PedMIDAS, a pediatric migraine disability tool.2 Children with chronic migraine also have a higher prevalence of anxiety and depression;3 these comorbidities impact quality of life as well.The authors also found an increased prevalence of adverse effects with medication. This highlights the need for personalized, evidence-based approaches to pediatric migraine treatment. Additional research emphasizes integrating behavioral and dietary interventions alongside pharmacological options, particularly for children with coexisting mental health conditions.4 Interventions such as cognitive behavioral therapy have been found to be beneficial for managing pediatric migraine.5The study’s comprehensive methodology and focus on a diverse set of pharmacological agents are commendable. The lack of significant quality-of-life improvements highlights an important limitation in current migraine management approaches. This aligns with findings that chronic conditions in pediatric populations often require multimodal interventions to address both physiological and psychosocial aspects. Future research should explore integrative approaches, including behavioral therapies and supplements, to develop holistic care strategies for this vulnerable population.Pharmacologic prophylaxis of pediatric migraine with pregabalin and topiramate appears to reduce headache intensity and frequency.Although the authors conclude that both levetiracetam and topiramate were associated with decreased headache frequency, in their meta-analysis, the calculated RoM of topiramate, with or without vitamin D3, was not significantly different from 1.0.